Pacira BioSciences Welcomes New Employees with Inducement Grants

Pacira BioSciences Welcomes New Talent

Pacira BioSciences, Inc. (Nasdaq: PCRX), a leader in the development of innovative non-opioid pain relief therapies, has recently made a significant announcement. The company provided inducement awards to support the onboarding of 15 new employees, marking a substantial step in their commitment to enhancing their workforce and operational capabilities.

Details of the Inducement Awards

On a recent date, Pacira granted stock options and restricted stock units as part of their Amended and Restated 2014 Inducement Plan. This move not only reflects Pacira's growth but is also in line with Nasdaq Listing Rule 5635(c)(4). The awards were ratified by the People & Compensation Committee of the Board of Directors without requiring stockholder approval, providing a clear path for these new hires to receive their awards swiftly.

Structure of the Stock Awards

Out of the 15 new hires, six members were granted stock options to acquire a total of 18,000 shares of Pacira common stock. Additionally, each new employee was awarded restricted stock units for an aggregate of 32,600 shares. The stock options carry a term of 10 years and come with a structured four-year vesting plan designed to promote long-term commitment. Specifically, 25 percent of the options will vest at the end of the first year of employment, while the remaining shares vest in equal quarterly installments over the next three years.

Understanding the Restricted Stock Units

In parallel to the stock options, the restricted stock units represent a promising opportunity for new employees as they correspond to one share of common stock each. Vesting for these units will occur annually in four equal parts, starting on a specific date. Each award is contingent upon the continued employment of the individual with Pacira, which indicates the company's focus on fostering a stable and committed workforce.

About Pacira BioSciences

Pacira BioSciences is dedicated to offering innovative, non-opioid therapies designed to improve patient outcomes. Their portfolio includes three primary non-opioid treatments, namely EXPAREL (bupivacaine liposome injectable suspension), ZILRETTA (triamcinolone acetonide extended-release injectable suspension), and the ioveraº technology, which provides immediate pain relief through targeted cold therapy. In addition to these established treatments, the company is at the forefront of research with PCRX-201, a novel gene therapy aimed at treating widespread diseases such as osteoarthritis.

Connecting with Pacira

To explore more about their innovative solutions or for inquiries, individuals can reach out to the dedicated investor relations or media contacts at Pacira. These communications channels reflect their commitment to transparency and engagement with stakeholders.

Frequently Asked Questions

What is the purpose of the inducement grants by Pacira BioSciences?

The inducement grants are a way to attract and retain top talent by providing new employees with stock options and restricted stock units as a material inducement for joining the company.

What types of awards were given to the new employees?

New employees received stock options and restricted stock units, allowing them to potentially benefit from the company's future growth and success.

How long is the vesting period for the stock options?

The stock options have a 10-year term with a four-year vesting schedule, promoting long-term employment and commitment to Pacira.

What products does Pacira currently offer?

Pacira offers EXPAREL, ZILRETTA, and iovera, all aimed at providing effective, non-opioid pain management solutions.

What is the significance of Nasdaq Listing Rule 5635(c)(4)?

This rule allows for the granting of stock awards to new hires without stockholder approval, facilitating a smoother process for companies looking to incentivize their employees.

About The Author

My name is Dylan Bailey, and I am 28 years old. I am an author and an expert on the stock market who specializes in publicly traded companies. Early fascination with the stock market inspired me to seek a finance degree and then delve deeply into the world of stocks. I have developed over the years my abilities to spot investment prospects, assess business performance, and analyze market trends.

My books and articles try to help regular investors understand the nuances of the stock market. Anyone can, in my opinion, make wise investment choices and succeed financially if they have the correct information and resources. In my writing, I combine in-depth research with practical insights and advice that can be put into action. This is done with the intention of assisting readers in navigating the constantly shifting landscape of publicly traded companies.

In addition to writing, I also host webinars and workshops, where I give presentations and share my knowledge with a wider audience. I also write for top financial journals and show up as a guest analyst on financial news shows. I like to travel, spend time with my family, and keep active by playing different sports when I'm not buried in market research.

My goal is to enable people to choose wisely and consciously in their investments, so taking charge of their financial futures. By my work, I hope to create a community of informed and self-assured investors prepared to take advantage of the chances presented by the stock market.

Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.